Grifols, S.A. or Evotec SE: Who Manages SG&A Costs Better?

Managing SG&A Costs: Grifols, S.A. vs. Evotec SE

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Grifols, S.A. and Evotec SE have demonstrated contrasting approaches to handling these costs. From 2014 to 2023, Grifols, S.A. consistently reported higher SG&A expenses, peaking at approximately €1.25 billion in 2023. In contrast, Evotec SE's expenses grew from €18 million in 2014 to €170 million in 2023, marking a significant increase of over 800%.

Despite Grifols, S.A.'s larger absolute expenses, their growth rate was more moderate, suggesting a stable cost management strategy. Meanwhile, Evotec SE's rapid increase in SG&A expenses reflects its aggressive expansion and investment in growth. This data provides valuable insights into each company's strategic priorities and operational efficiencies, offering a glimpse into their financial health and future trajectories.